Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.330
-0.010 (-0.75%)
At close: Sep 11, 2026, 4:00 PM EDT
1.350
+0.020 (1.50%)
After-hours: Sep 11, 2026, 7:30 PM EDT
Coherus Oncology Revenue
Coherus Oncology had revenue of $14.31M in the quarter ending June 30, 2026, with 39.53% growth. This brings the company's revenue in the last twelve months to $50.94M. In the year 2025, Coherus Oncology had annual revenue of $42.17M with 59.81% growth.
Revenue (ttm)
$50.94M
Revenue Growth
+59.81%
P/S Ratio
4.03
Revenue / Employee
$353,722
Employees
144
Market Cap
205.49M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 42.17M | 15.78M | 59.81% |
| Dec 31, 2024 | 26.39M | -230.86M | -89.74% |
| Dec 31, 2023 | 257.24M | 46.20M | 21.89% |
| Dec 31, 2022 | 211.04M | -115.51M | -35.37% |
| Dec 31, 2021 | 326.55M | -149.27M | -31.37% |
| Dec 31, 2020 | 475.82M | 119.75M | 33.63% |
| Dec 31, 2019 | 356.07M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 1.56M | -188.55M | -99.18% |
| Dec 31, 2016 | 190.11M | 160.07M | 532.82% |
| Dec 31, 2015 | 30.04M | -1.07M | -3.42% |
| Dec 31, 2014 | 31.11M | 28.36M | 1,030.72% |
| Dec 31, 2013 | 2.75M | 852.00K | 44.87% |
| Dec 31, 2012 | 1.90M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 80.62M |
| Precision BioSciences | 45.06M |
| Voyager Therapeutics | 34.46M |
| Alpha Cognition | 15.26M |
| Armata Pharmaceuticals | 5.54M |
| Oramed Pharmaceuticals | 2.00M |
CHRS News
- 12 days ago - Coherus to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 25 days ago - Coherus Oncology issuing special dividend of biosimilar contingent value rights - TheFly
- 25 days ago - Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights - GlobeNewsWire
- 5 weeks ago - Coherus Oncology price target lowered to $10 from $12 at Guggenheim - TheFly
- 5 weeks ago - Coherus Oncology reports Q2 EPS (19c), consensus (12c) - TheFly
- 5 weeks ago - Coherus Oncology Earnings Call Transcript: Q2 2026 - Transcripts
- 5 weeks ago - Coherus Oncology Earnings release: Q2 2026 - Filings
- 5 weeks ago - Coherus Oncology Quarterly report: Q2 2026 - Filings